Analysis of Frailty Syndrome Within the Framework of the Innovation Fund Project PRÄP-GO (ANA-PRÄP-GO)

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · May 10, 2021

Keywords

ClinConnect Summary

The PRÄP-GO clinical trial is studying a condition called Frailty Syndrome, which affects the strength and health of older adults. This study aims to better understand and describe the different aspects of frailty in patients who are part of the PRÄP-GO project. If you are over 70 years old and have planned surgery, you may be eligible to join the study, especially if you are not considered frail according to specific health criteria. There are also opportunities for family members and healthcare professionals involved in the project to participate.

Participants in this trial can expect to contribute to important research that may improve care for frail and older patients. The study is currently recruiting, and there are specific guidelines to ensure that participants are safe and able to take part in the assessments. It’s important to note that there are certain health conditions that may prevent some individuals from joining, but there are no exclusions based on frailty for those in the main PRÄP-GO group. This research is a great opportunity to help advance our understanding of frailty and improve patient outcomes in the future.

Gender

ALL

Eligibility criteria

• PG cohort:
• • Inclusion criteria
• • Consent given and inclusion in PRÄP-GO
• • Patient capable of giving consent or existing legal guardian in the case of patients not capable of giving consent
• • Exclusion criteria
• • - None
• NFC cohort:
• • Inclusion criteria
• • Patient capable of giving consent or existing legal guardian in the case of patients not capable of giving consent
• • Age ≥ 70 years
• • Elective surgery planned
• • Expected anesthesia duration\> 60 min
• • No frailty syndrome (0 positive out of 5 standardized parameters) according to the physical frailty phenotype (Fried et al., 2001)
• • Exclusion criteria
• • Severe cardiac or pulmonary disease (NYHA IV, Gold IV)
• • Intracranial interventions
• • Moribund patients (palliative situation)
• • Patients with a neuropsychiatric clinical picture or severe hearing and / or visual acuity impairment (not compensated by visual or hearing aids), which limit the performance of the neurocognitive tests
• • Insufficient language skills
• • Participation in another interventional rehabilitation study or a study according to the German Drug Law or the medical Device Law that has not been approved by the study leader (Exception: parallel participation in adjuvant therapy study).
• NO cohort:
• • Inclusion criteria
• • - Age ≥ 70 years
• • No elective surgery planned
• • No surgery within 6 months prior to study enrollment
• • Exclusion criteria - See NFC cohort
• GB cohort:
• • Inclusion criterion
• • - Doctor, nurse or therapist from the cooperation partners of PRAEP-GO who were involved in the project
• • Exclusion criterion
• • - Language barrier
• Relatives:
• • Inclusion criteria
• • Member of a patient in the PRÄP-GO cohort
• • Age ≥ 18 years
• • Exclusion criterion
• • - Language barrier